PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer

[11] Sørlie T(2010)Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia Mol Cancer 7 11-144

[12] Perou CM(2017)Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes Clin Sarcoma Res. 3 128-6358

[13] Tibshirani R(2017)Impact of preferentially expressed antigen of melanoma on the prognosis of Hepatocellular Carcinoma Gastrointest Tumors 101 137-9532

[14] Aas T(2016)The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients Lung Cancer 37 6349-578

[15] Geisler S(2016)Diagnostic marker signature for esophageal cancer from transcriptome analysis Tumour Biol 8 9522-329

[16] Johnsen H(2015)Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics Int J Clin Exp Pathol. 7 575-899

[17] Hastie T(2013)Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med. 9 947-151

[18] Eisen MB(2018)NY-ESO-1 based immunotherapy of cancer: current perspectives Front Immunol. 11 311-365

[19] Van De Rijn M(2018)A comprehensive immunologic portrait of triple-negative breast cancer Transl Oncol. 87 809-403

[20] Jeffrey SS(2008)Aberrant hypomethylation of the cancer—testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia Ann Hematol 36 895-549

[11] Sørlie T(2010)Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia Mol Cancer 7 11-144

[12] Perou CM(2017)Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes Clin Sarcoma Res. 3 128-6358

[13] Tibshirani R(2017)Impact of preferentially expressed antigen of melanoma on the prognosis of Hepatocellular Carcinoma Gastrointest Tumors 101 137-9532

[14] Aas T(2016)The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients Lung Cancer 37 6349-578

[15] Geisler S(2016)Diagnostic marker signature for esophageal cancer from transcriptome analysis Tumour Biol 8 9522-329

[16] Johnsen H(2015)Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics Int J Clin Exp Pathol. 7 575-899

[17] Hastie T(2013)Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med. 9 947-151

[18] Eisen MB(2018)NY-ESO-1 based immunotherapy of cancer: current perspectives Front Immunol. 11 311-365

[19] Van De Rijn M(2018)A comprehensive immunologic portrait of triple-negative breast cancer Transl Oncol. 87 809-403

[20] Jeffrey SS(2008)Aberrant hypomethylation of the cancer—testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia Ann Hematol 36 895-549